AbbVie Launches Crohn's and Colitis Scholarship to Support Students Living With Inflammatory Bowel Disease

Article

AbbVie has announced the launch of the AbbVie Crohn's & Colitis Scholarship, designed to provide financial support for exceptional students living with inflammatory bowel disease (IBD) as they pursue higher education goals.

PRESS RELEASE

NORTH CHICAGO, Ill.

,

Dec. 4, 2015

/PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the launch of the AbbVie Crohn's & Colitis Scholarship, designed to provide financial support for exceptional students living with inflammatory bowel disease (IBD) as they pursue higher education goals. Fifteen scholars will be selected to receive

$15,000

each for the 2016-2017 school year. The AbbVie Crohn's & Colitis Scholarship is currently accepting applications.

"At AbbVie, we are focused on addressing the world's most difficult health challenges through a comprehensive and responsible approach," said

Tracie Haas

, vice president corporate responsibility, brand and communications, AbbVie. "Students living with inflammatory bowel disease face significant obstacles while they pursue higher education, and the AbbVie Crohn's & Colitis Scholarship aims to empower students to achieve their educational goals."

Approximately 1.6 million Americans live with IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC).1 These diseases cause inflammation and may damage the gastrointestinal tract, resulting in symptoms such as diarrhea, abdominal pain, rectal bleeding, weight loss and fatigue.1 When students with IBD experience symptoms, it can cause them to miss school and experience difficulty sitting for exams.2

About the AbbVie Crohn's & Colitis Scholarship

The scholarship is available to students living with IBD, including CD or UC, who are seeking a trade school diploma or an associate, undergraduate or graduate degree from an accredited U.S. trade school, college or university. Recipients will be chosen based on academic excellence, community involvement, written response to an essay question and ability to serve as a positive role model for the IBD community. The application period will close on

March 25, 2016

,

10 a.m. (CT)

, and final notification to scholarship winners will be made by

April 29, 2016

.

It is not necessary for applicants to have taken, currently take or intend to take in the future any medicine or product marketed by AbbVie; this will not be a consideration in the recipient selection criteria. Employees of AbbVie and their immediate family members are not eligible. Healthcare providers and their immediate family members are not eligible. Patients contracted by AbbVie through Patient Health Perspectives ("SPEAK Network") are not eligible.

For access to the online application, additional information about the application process and full eligibility details, please visit www.CrohnsandColitisScholarship.com.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.